Common Side Effects of Lurbinectedin
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, causes hematologic toxicities like neutropenia (57% of patients, severe in 33%), anemia (53%, severe in 25%), and thrombocytopenia (37%, severe in 17%). These often require dose delays or reductions.[1][2]
Gastrointestinal issues include nausea (55%), fatigue (50%), decreased appetite (40%), vomiting (33%), diarrhea (22%), and constipation (19%).[1]
Severe or Life-Threatening Risks
Myelosuppression can lead to febrile neutropenia (8%, with deaths reported) and sepsis. Severe anemia may cause fatal bleeding or infections. Rhabdomyolysis occurs in 4% (severe in 1%). Respiratory failure and pneumonia are notable, sometimes fatal.[1][2]
Infusion-related reactions (skin rash, pruritus, bronchospasm) affect 2%.[1]
Effects on Liver, Kidneys, and Other Organs
Elevated liver enzymes (ALT 35%, AST 29%, bilirubin 12%) signal hepatotoxicity. Increased creatinine (8%) indicates kidney stress. Hyperglycemia (15%) and hyponatremia (11%) are common lab abnormalities.[1]
Long-Term and Patient-Reported Concerns
Peripheral neuropathy (17%), dyspnea (16%), and musculoskeletal pain (15%) persist or worsen with cycles. Hair loss (alopecia 14%) and edema (12%) affect quality of life. Patients report severe fatigue lasting weeks post-infusion.[2][3]
Managing Side Effects
Monitor complete blood counts weekly for first two cycles, then every other cycle. Hold doses for absolute neutrophil count below 1,500/μL or platelets below 100,000/μL. Use G-CSF for neutropenia prophylaxis. Premedicate with antiemetics for nausea.[1][2]
FDA warns of embryo-fetal toxicity; advise contraception.[1]
[1]: Zepzelca (lurbinectedin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-PI.pdf
[2]: FDA Approval Summary for Lurbinectedin, Clinical Pharmacology & Therapeutics, https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2192
[3]: Patient Information from Drugs.com, https://www.drugs.com/zepzelca.html